Why the study?
There is uncertainty regarding which anticoagulant should be used in patients with non-valvular AF and valvular heart disease.
Do direct-acting oral anticoagulants reduce systemic embolism and stroke in patients with non-valvular atrial fibrillation with valvular heart disease compared to warfarin?
Population
21,185 patients with non-valvular AF with valvular heart disease across seven studies
Comparison
DOACs vs warfarin
Design
Systematic review and meta-analysis
Authors
Loading...
Supports DOAC preference over warfarin for AF with valvular disease; extends prior RCT meta-analyses with updated synthesis of eight trials.
Do direct-acting oral anticoagulants reduce systemic embolism and stroke in patients with non-valvular atrial fibrillation with valvular heart disease compared to warfarin?
In patients with non-valvular atrial fibrillation and valvular heart disease, DOACs significantly reduce the risk of stroke, systemic embolism, and intracranial hemorrhage compared to warfarin without increasing major bleeding.
Martha et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: